{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:05:42Z","timestamp":1791515142764,"version":"4.3.4"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04591-0","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T05:43:13Z","timestamp":1761370993000},"page":"4655-4700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic impacts of oral anti-diabetic drugs on Inflammatory Bowel Disease (IBD), a comprehensive review of clinical and preclinical studies"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-5619","authenticated-orcid":false,"given":"Amirhossein","family":"Niknejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-5555","authenticated-orcid":false,"given":"Yasamin","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4631-8617","authenticated-orcid":false,"given":"Mohammad Amin","family":"Nazari Manesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-7035","authenticated-orcid":false,"given":"Maryam","family":"Navabakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6100-3667","authenticated-orcid":false,"given":"Amirreza","family":"Peyrovinasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2678-5600","authenticated-orcid":false,"given":"Helia","family":"Mavaddat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8104-0769","authenticated-orcid":false,"given":"Mahdis Sadat","family":"Miri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5949-429X","authenticated-orcid":false,"given":"Mahdiyeh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3366","authenticated-orcid":false,"given":"Dietrich","family":"B\u00fcsselberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9961-9097","authenticated-orcid":false,"given":"Amir Hossein","family":"Abdolghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"10","key":"4591_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00535-022-01896-2","volume":"57","author":"KH Allin","year":"2022","unstructured":"Allin KH, Jensen CB, Jacobsen RK, Jess T (2022) Metformin use is not associated with reduced risk of older onset inflammatory bowel disease: a Danish nationwide population-based study. J Gastroenterol 57(10):761\u2013769. https:\/\/doi.org\/10.1007\/s00535-022-01896-2","journal-title":"J Gastroenterol"},{"issue":"1","key":"4591_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000525925","volume":"104","author":"A Andoh","year":"2023","unstructured":"Andoh A, Nishida A (2023) Alteration of the gut microbiome in inflammatory bowel disease. Digestion 104(1):16\u201323. https:\/\/doi.org\/10.1159\/000525925","journal-title":"Digestion"},{"issue":"12","key":"4591_CR3","doi-asserted-by":"publisher","first-page":"6303","DOI":"10.4049\/jimmunol.164.12.6303","volume":"164","author":"PG Andres","year":"2000","unstructured":"Andres PG, Beck PL, Mizoguchi E, Mizoguchi A, Bhan AK, Dawson T, Kuziel WA, Maeda N, MacDermott RP, Podolsky DK, Reinecker HC (2000) Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 164(12):6303\u20136312. https:\/\/doi.org\/10.4049\/jimmunol.164.12.6303","journal-title":"J Immunol"},{"issue":"12","key":"4591_CR4","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1021\/jf2008925","volume":"59","author":"I And\u00fajar","year":"2011","unstructured":"And\u00fajar I, Recio MC, Giner RM, Cienfuegos-Jovellanos E, Laghi S, Muguerza B, R\u00edos JL (2011) Inhibition of ulcerative colitis in mice after oral administration of a polyphenol-enriched cocoa extract is mediated by the inhibition of STAT1 and STAT3 phosphorylation in colon cells. J Agric Food Chem 59(12):6474\u20136483","journal-title":"J Agric Food Chem"},{"key":"4591_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/620839","volume":"2012","author":"V Annese","year":"2012","unstructured":"Annese V, Rogai F, Settesoldi A, Bagnoli S (2012) Ppar\u03b3 in inflammatory bowel disease. PPAR Res 2012:620839. https:\/\/doi.org\/10.1155\/2012\/620839","journal-title":"PPAR Res"},{"issue":"7","key":"4591_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ncpgasthep0846","volume":"4","author":"TM Antalis","year":"2007","unstructured":"Antalis TM, Shea-Donohue T, Vogel SN, Sears C, Fasano A (2007) Mechanisms of disease: protease functions in intestinal mucosal pathobiology. Nat Clin Pract Gastroenterol Hepatol 4(7):393\u2013402","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"4591_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109368","volume":"335","author":"HH Arab","year":"2021","unstructured":"Arab HH, Al-Shorbagy MY, Saad MA (2021a) Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: targeting AMPK\/mTOR, HMGB1\/RAGE and Nrf2\/HO-1 pathways. Chem Biol Interact 335:109368. https:\/\/doi.org\/10.1016\/j.cbi.2021.109368","journal-title":"Chem Biol Interact"},{"key":"4591_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119295","volume":"273","author":"HH Arab","year":"2021","unstructured":"Arab HH, Eid AH, Mahmoud AM, Senousy MA (2021b) Linagliptin mitigates experimental inflammatory bowel disease in rats by targeting inflammatory and redox signaling. Life Sci 273:119295. https:\/\/doi.org\/10.1016\/j.lfs.2021.119295","journal-title":"Life Sci"},{"key":"4591_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.114919","volume":"391","author":"EA Arafa","year":"2020","unstructured":"Arafa EA, Mohamed WR, Zaher DM, Omar HA (2020) Gliclazide attenuates acetic acid-induced colitis via the modulation of PPAR\u03b3, NF-\u03baB and MAPK signaling pathways. Toxicol Appl Pharmacol 391:114919. https:\/\/doi.org\/10.1016\/j.taap.2020.114919","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"4591_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/75068","volume":"6","author":"R Atreya","year":"2000","unstructured":"Atreya R, Mudter J, Finotto S, M\u00fcllberg J, Jostock T, Wirtz S, Sch\u00fctz M, Bartsch B, Holtmann M, Becker C (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6(5):583\u2013588","journal-title":"Nat Med"},{"issue":"6","key":"4591_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1365-2796.2008.01953.x","volume":"263","author":"I Atreya","year":"2008","unstructured":"Atreya I, Atreya R, Neurath M (2008) NF-\u03bab in inflammatory bowel disease. J Intern Med 263(6):591\u2013596","journal-title":"J Intern Med"},{"issue":"8","key":"4591_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/ncprheum0222","volume":"2","author":"D Aud","year":"2006","unstructured":"Aud D, Peng SL (2006) Mechanisms of disease: transcription factors in inflammatory arthritis. Nat Clin Pract Rheumatol 2(8):434\u2013442","journal-title":"Nat Clin Pract Rheumatol"},{"key":"4591_CR13","doi-asserted-by":"publisher","unstructured":"B, S., R. C. Satish Kumar, M. B and K. K. C (2024). \"A comprehensive narrative review of drug interactions between traveler\u2019s diarrhea medications and chronic therapies: implications for clinical practice.\" Cureus 16(9), e70213 https:\/\/doi.org\/10.7759\/cureus.70213.","DOI":"10.7759\/cureus.70213"},{"issue":"3","key":"4591_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/mi.2012.89","volume":"6","author":"CC Bain","year":"2013","unstructured":"Bain CC, Scott CL, Uronen-Hansson H, Gudjonsson S, Jansson O, Grip O, Guilliams M, Malissen B, Agace WW, Mowat AM (2013) Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol 6(3):498\u2013510. https:\/\/doi.org\/10.1038\/mi.2012.89","journal-title":"Mucosal Immunol"},{"issue":"4","key":"4591_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/MOG.0b013e3281c55eb2","volume":"23","author":"G Bamias","year":"2007","unstructured":"Bamias G, Cominelli F (2007) Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol 23(4):365\u2013369","journal-title":"Curr Opin Gastroenterol"},{"issue":"12","key":"4591_CR16","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1016\/j.cgh.2020.09.023","volume":"19","author":"G Bamias","year":"2021","unstructured":"Bamias G, Cominelli F (2021) Exploring the early phase of Crohn\u2019s disease. Clin Gastroenterol Hepatol 19(12):2469\u20132480. https:\/\/doi.org\/10.1016\/j.cgh.2020.09.023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"4591_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.31887\/DCNS.2019.21.1\/bblendin","volume":"21","author":"BB Bendlin","year":"2019","unstructured":"Bendlin BB (2019) Antidiabetic therapies and Alzheimer disease. Dialogues Clin Neurosci 21(1):83\u201391. https:\/\/doi.org\/10.31887\/DCNS.2019.21.1\/bblendin","journal-title":"Dialogues Clin Neurosci"},{"issue":"9","key":"4591_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1136\/gut.2007.122143","volume":"57","author":"CN Bernstein","year":"2008","unstructured":"Bernstein CN, Shanahan F (2008) Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 57(9):1185\u20131191","journal-title":"Gut"},{"issue":"8","key":"4591_CR19","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.4239\/wjd.v12.i8.1248","volume":"12","author":"JAJ Bower","year":"2021","unstructured":"Bower JAJ, O\u2019Flynn L, Kakad R, Aldulaimi D (2021) Effect of inflammatory bowel disease treatments on patients with diabetes mellitus. World J Diabetes 12(8):1248\u20131254. https:\/\/doi.org\/10.4239\/wjd.v12.i8.1248","journal-title":"World J Diabetes"},{"issue":"3","key":"4591_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1365-2249.2009.04033.x","volume":"158","author":"O Broom","year":"2009","unstructured":"Broom O, Widjaya B, Troelsen J, Olsen J, Nielsen O (2009) Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol 158(3):272\u2013280","journal-title":"Clin Exp Immunol"},{"key":"4591_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1330797","volume":"15","author":"A Buczy\u0144ska","year":"2024","unstructured":"Buczy\u0144ska A, Sidorkiewicz I, Kr\u0119towski AJ, Adamska A (2024) Examining the clinical relevance of metformin as an antioxidant intervention. Front Pharmacol 15:1330797. https:\/\/doi.org\/10.3389\/fphar.2024.1330797","journal-title":"Front Pharmacol"},{"issue":"8","key":"4591_CR22","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3109\/00365521.2015.1014407","volume":"50","author":"J Burisch","year":"2015","unstructured":"Burisch J, Munkholm P (2015) The epidemiology of inflammatory bowel disease. Scand J Gastroenterol 50(8):942\u2013951. https:\/\/doi.org\/10.3109\/00365521.2015.1014407","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"4591_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s1734-1140(13)71076-4","volume":"65","author":"DSP Byrav","year":"2013","unstructured":"Byrav DSP, Medhi B, Prakash A, Chakrabarti A, Vaiphei K, Khanduja KL (2013) Comparative evaluation of different doses of PPAR-\u03b3 agonist alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats. Pharmacol Rep 65(4):951\u2013959. https:\/\/doi.org\/10.1016\/s1734-1140(13)71076-4","journal-title":"Pharmacol Rep"},{"key":"4591_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2147\/dddt.S37647","volume":"7","author":"A Capuano","year":"2013","unstructured":"Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K (2013) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy\u2013focus on alogliptin. Drug Des Devel Ther 7:989\u20131001. https:\/\/doi.org\/10.2147\/dddt.S37647","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"4591_CR25","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1196\/annals.1326.006","volume":"1072","author":"E Cario","year":"2006","unstructured":"Cario E, Podolsky DK (2006) Toll-like receptor signaling and its relevance to intestinal inflammation. Ann N Y Acad Sci 1072(1):332\u2013338","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"4591_CR26","first-page":"347","volume":"62","author":"K Celinski","year":"2011","unstructured":"Celinski K, Dworzanski T, Korolczuk A, Piasecki R, Slomka M, Madro A, Fornal R (2011a) Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats. J Physiol Pharmacol 62(3):347\u2013356","journal-title":"J Physiol Pharmacol"},{"key":"4591_CR27","doi-asserted-by":"publisher","unstructured":"Celinski, K., T. Dworzanski, A. Korolczuk, M. Slomka, S. Radej, H. Cichoz-Lach and A. Madro (2011). \"Activated and inactivated PPARs-\u03b3 modulate experimentally induced colitis in rats.\" Med Sci Monit 17(4), Br116\u2013124 https:\/\/doi.org\/10.12659\/msm.881712.","DOI":"10.12659\/msm.881712"},{"issue":"6","key":"4591_CR28","first-page":"631","volume":"63","author":"K Celinski","year":"2012","unstructured":"Celinski K, Dworzanski T, Fornal R, Korolczuk A, Madro A, Slomka M (2012) Comparison of the anti-inflammatory and therapeutic actions of PPAR-gamma agonists rosiglitazone and troglitazone in experimental colitis. J Physiol Pharmacol 63(6):631\u2013640","journal-title":"J Physiol Pharmacol"},{"issue":"5","key":"4591_CR29","first-page":"587","volume":"64","author":"K Celinski","year":"2013","unstructured":"Celinski K, Dworzanski T, Fornal R, Korolczuk A, Madro A, Brzozowski T, Slomka M (2013) Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis. J Physiol Pharmacol 64(5):587\u2013595","journal-title":"J Physiol Pharmacol"},{"key":"4591_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00761","volume":"9","author":"L Chen","year":"2018","unstructured":"Chen L, Wang J, You Q, He S, Meng Q, Gao J, Wu X, Shen Y, Sun Y, Wu X, Xu Q (2018) Activating AMPK to restore tight junction assembly in intestinal epithelium and to attenuate experimental colitis by metformin. Front Pharmacol 9:761. https:\/\/doi.org\/10.3389\/fphar.2018.00761","journal-title":"Front Pharmacol"},{"issue":"14","key":"4591_CR31","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1021\/jm960132w","volume":"39","author":"DJ Crawford","year":"1996","unstructured":"Crawford DJ, Maddocks JL, Jones DN, Szawlowski P (1996) Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J Med Chem 39(14):2690\u20132695","journal-title":"J Med Chem"},{"issue":"11","key":"4591_CR32","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2165\/00003495-200161110-00008","volume":"61","author":"CR Culy","year":"2001","unstructured":"Culy CR, Jarvis B (2001) Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 61(11):1625\u20131660. https:\/\/doi.org\/10.2165\/00003495-200161110-00008","journal-title":"Drugs"},{"key":"4591_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.591561","volume":"11","author":"GHO da Rocha","year":"2020","unstructured":"da Rocha GHO, de Paula-Silva M, Broering MF, Scharf P, Matsuyama L, Maria-Engler SS, Farsky SHP (2020) Pioglitazone-mediated attenuation of experimental colitis relies on cleaving of annexin A1 released by macrophages. Front Pharmacol 11:591561. https:\/\/doi.org\/10.3389\/fphar.2020.591561","journal-title":"Front Pharmacol"},{"issue":"7","key":"4591_CR34","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/j.1440-1746.2011.06719.x","volume":"26","author":"A Daneshmand","year":"2011","unstructured":"Daneshmand A, Mohammadi H, Rahimian R, Habibollahi P, Fakhfouri G, Talab SS, Mehr SE, Dehpour AR (2011) Chronic lithium administration ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats; potential role for adenosine triphosphate sensitive potassium channels. J Gastroenterol Hepatol 26(7):1174\u20131181. https:\/\/doi.org\/10.1111\/j.1440-1746.2011.06719.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"4591_CR35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.gene.6364398","volume":"8","author":"P De Jager","year":"2007","unstructured":"De Jager P, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, Belaiche J, Vermeire S, Farwell L, Goris A (2007) The role of the toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 8(5):387\u2013397","journal-title":"Genes Immun"},{"issue":"2","key":"4591_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","volume":"65","author":"R DeFronzo","year":"2016","unstructured":"DeFronzo R, Fleming GA, Chen K, Bicsak TA (2016) Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism 65(2):20\u201329. https:\/\/doi.org\/10.1016\/j.metabol.2015.10.014","journal-title":"Metabolism"},{"issue":"1","key":"4591_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/jcmm.13342","volume":"22","author":"J Deng","year":"2018","unstructured":"Deng J, Zeng L, Lai X, Li J, Liu L, Lin Q, Chen Y (2018) Metformin protects against intestinal barrier dysfunction via AMPK\u03b11-dependent inhibition of JNK signalling activation. J Cell Mol Med 22(1):546\u2013557. https:\/\/doi.org\/10.1111\/jcmm.13342","journal-title":"J Cell Mol Med"},{"issue":"5","key":"4591_CR38","doi-asserted-by":"publisher","first-page":"899","DOI":"10.5114\/aoms.2012.31621","volume":"8","author":"G Derosa","year":"2012","unstructured":"Derosa G, Maffioli P (2012) \u03b1-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci 8(5):899\u2013906. https:\/\/doi.org\/10.5114\/aoms.2012.31621","journal-title":"Arch Med Sci"},{"issue":"11","key":"4591_CR39","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1042\/cs20180167","volume":"132","author":"D Di Fusco","year":"2018","unstructured":"Di Fusco D, Dinallo V, Monteleone I, Laudisi F, Marafini I, Franz\u00e8 E, Di Grazia A, Dwairi R, Colantoni A, Ortenzi A, Stolfi C, Monteleone G (2018) Metformin inhibits inflammatory signals in the gut by controlling AMPK and p38 MAP kinase activation. Clin Sci (Lond) 132(11):1155\u20131168. https:\/\/doi.org\/10.1042\/cs20180167","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"4591_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s13181-010-0064-z","volume":"6","author":"PP Dougherty","year":"2010","unstructured":"Dougherty PP, Klein-Schwartz W (2010) Octreotide\u2019s role in the management of sulfonylurea-induced hypoglycemia. J Med Toxicol 6(2):199\u2013206. https:\/\/doi.org\/10.1007\/s13181-010-0064-z","journal-title":"J Med Toxicol"},{"issue":"1","key":"4591_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jcmgh.2021.03.002","volume":"12","author":"B Drury","year":"2021","unstructured":"Drury B, Hardisty G, Gray RD, Ho GT (2021) Neutrophil extracellular traps in inflammatory bowel disease: pathogenic mechanisms and clinical translation. Cell Mol Gastroenterol Hepatol 12(1):321\u2013333. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.03.002","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"4591_CR42","first-page":"683","volume":"61","author":"T Dworzanski","year":"2010","unstructured":"Dworzanski T, Celinski K, Korolczuk A, Slomka M, Radej S, Czechowska G, Madro A, Cichoz-Lach H (2010) Influence of the peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) agonist, rosiglitazone and antagonist, biphenol-A-diglicydyl ether (BADGE) on the course of inflammation in the experimental model of colitis in rats. J Physiol Pharmacol 61(6):683\u2013693","journal-title":"J Physiol Pharmacol"},{"key":"4591_CR43","doi-asserted-by":"publisher","unstructured":"Dzi\u0105bowska-Grabias, K., M. Sztanke, P. Zaj\u0105c, M. Celejewski, K. Kurek, S. Szkutnicki, P. Korga, W. Bulikowski and K. Sztanke (2021). \"Antioxidant therapy in inflammatory bowel diseases.\" Antioxidants (Basel) 10(3) https:\/\/doi.org\/10.3390\/antiox10030412.","DOI":"10.3390\/antiox10030412"},{"key":"4591_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2022.115906","volume":"438","author":"MS El-Ghannam","year":"2022","unstructured":"El-Ghannam MS, Saad MA, Nassar NN, El-Yamany MF, El-Bahy AAZ (2022) Linagliptin ameliorates acetic acid-induced colitis via modulating AMPK\/SIRT1\/PGC-1\u03b1 and JAK2\/STAT3 signaling pathway in rats. Toxicol Appl Pharmacol 438:115906. https:\/\/doi.org\/10.1016\/j.taap.2022.115906","journal-title":"Toxicol Appl Pharmacol"},{"key":"4591_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010040","author":"MK ElMahdy","year":"2021","unstructured":"ElMahdy MK, Antar SA, Elmahallawy EK, Abdo W, Hijazy HHA, Albrakati A, Khodir AE (2021) A novel role of dapagliflozin in mitigation of acetic acid-induced ulcerative colitis by modulation of monocyte chemoattractant protein 1 (MCP-1)\/nuclear factor-kappa B (NF-\u03baB)\/interleukin-18 (IL-18). Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10010040","journal-title":"Biomedicines"},{"issue":"2","key":"4591_CR46","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/08923973.2021.1878214","volume":"43","author":"NA El-Mahdy","year":"2021","unstructured":"El-Mahdy NA, El-Sayad ME, El-Kadem AH, Abu-Risha SE (2021) Metformin alleviates inflammation in oxazolone induced ulcerative colitis in rats: plausible role of sphingosine kinase 1\/sphingosine 1 phosphate signaling pathway. Immunopharmacol Immunotoxicol 43(2):192\u2013202. https:\/\/doi.org\/10.1080\/08923973.2021.1878214","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"4","key":"4591_CR47","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10787-021-00818-7","volume":"29","author":"MA El-Rous","year":"2021","unstructured":"El-Rous MA, Saber S, Raafat EM, Ahmed AAE (2021) Dapagliflozin, an SGLT2 inhibitor, ameliorates acetic acid-induced colitis in rats by targeting NF\u03baB\/AMPK\/NLRP3 axis. Inflammopharmacology 29(4):1169\u20131185. https:\/\/doi.org\/10.1007\/s10787-021-00818-7","journal-title":"Inflammopharmacology"},{"issue":"6","key":"4591_CR48","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","volume":"20","author":"M Foretz","year":"2014","unstructured":"Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B (2014) Metformin: from mechanisms of action to therapies. Cell Metab 20(6):953\u2013966. https:\/\/doi.org\/10.1016\/j.cmet.2014.09.018","journal-title":"Cell Metab"},{"issue":"10","key":"4591_CR49","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.molmed.2023.07.008","volume":"29","author":"S Geertsema","year":"2023","unstructured":"Geertsema S, Bourgonje AR, Fagundes RR, Gacesa R, Weersma RK, van Goor H, Mann GE, Dijkstra G, Faber KN (2023) The NRF2\/Keap1 pathway as a therapeutic target in inflammatory bowel disease. Trends Mol Med 29(10):830\u2013842. https:\/\/doi.org\/10.1016\/j.molmed.2023.07.008","journal-title":"Trends Mol Med"},{"issue":"10","key":"4591_CR50","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0006-2952(97)00018-X","volume":"53","author":"M Goppelt-Struebe","year":"1997","unstructured":"Goppelt-Struebe M (1997) Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. Biochem Pharmacol 53(10):1389\u20131395","journal-title":"Biochem Pharmacol"},{"issue":"8926","key":"4591_CR51","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/s0140-6736(94)92831-2","volume":"344","author":"MB Grisham","year":"1994","unstructured":"Grisham MB (1994a) Oxidants and free radicals in inflammatory bowel disease. Lancet 344(8926):859\u2013861. https:\/\/doi.org\/10.1016\/s0140-6736(94)92831-2","journal-title":"Lancet"},{"issue":"8926","key":"4591_CR52","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(94)92831-2","volume":"344","author":"MB Grisham","year":"1994","unstructured":"Grisham MB (1994b) Oxidants and free radicals in inflammatory bowel disease. Lancet 344(8926):859\u2013861","journal-title":"Lancet"},{"key":"4591_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.149291","volume":"690","author":"S Hahn","year":"2024","unstructured":"Hahn S, Kim G, Jin SM, Kim JH (2024) Protective effects of metformin in the pro-inflammatory cytokine induced intestinal organoids injury model. Biochem Biophys Res Commun 690:149291. https:\/\/doi.org\/10.1016\/j.bbrc.2023.149291","journal-title":"Biochem Biophys Res Commun"},{"issue":"6 Suppl 1","key":"4591_CR54","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/s1262-3636(14)72693-x","volume":"40","author":"S Halimi","year":"2014","unstructured":"Halimi S, Verg\u00e8s B (2014) Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab 40(6 Suppl 1):S28-34. https:\/\/doi.org\/10.1016\/s1262-3636(14)72693-x","journal-title":"Diabetes Metab"},{"issue":"6","key":"4591_CR55","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/s0025-7125(16)30108-0","volume":"78","author":"SB Hanauer","year":"1994","unstructured":"Hanauer SB, Baert F (1994) Medical therapy of inflammatory bowel disease. Med Clin North Am 78(6):1413\u20131426. https:\/\/doi.org\/10.1016\/s0025-7125(16)30108-0","journal-title":"Med Clin North Am"},{"key":"4591_CR56","doi-asserted-by":"publisher","unstructured":"Harsch, I. A., R. H. Kaestner and P. C. Konturek (2018). \"Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management.\" J Physiol Pharmacol 69(4) https:\/\/doi.org\/10.26402\/jpp.2018.4.15.","DOI":"10.26402\/jpp.2018.4.15"},{"issue":"13","key":"4591_CR57","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1096\/fj.04-1642fje","volume":"18","author":"E Hollenbach","year":"2004","unstructured":"Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M (2004) Inhibition of p38 MAP kinase-and RICK\/NF-\u03baB-signaling suppresses inflammatory bowel disease. FASEB J 18(13):1550\u20131552","journal-title":"FASEB J"},{"issue":"1","key":"4591_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/brx2.52","volume":"2","author":"L Hu","year":"2024","unstructured":"Hu L, Wang W, Chen X, Bai G, Ma L, Yang X, Shu Q, Li X (2024) Prospects of antidiabetic drugs in the treatment of neurodegenerative disease. Brain-X 2(1):e52. https:\/\/doi.org\/10.1002\/brx2.52","journal-title":"Brain-X"},{"issue":"2","key":"4591_CR59","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s10753-019-01138-3","volume":"43","author":"Y Huang","year":"2020","unstructured":"Huang Y, Wang C, Tian X, Mao Y, Hou B, Sun Y, Gu X, Ma Z (2020) Pioglitazone attenuates experimental colitis-associated hyperalgesia through improving the intestinal barrier dysfunction. Inflammation 43(2):568\u2013578. https:\/\/doi.org\/10.1007\/s10753-019-01138-3","journal-title":"Inflammation"},{"issue":"8","key":"4591_CR60","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41579-025-01163-0","volume":"23","author":"ID Iliev","year":"2025","unstructured":"Iliev ID, Ananthakrishnan AN, Guo C-J (2025) Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities. Nat Rev Microbiol 23(8):509\u2013524. https:\/\/doi.org\/10.1038\/s41579-025-01163-0","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"4591_CR61","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1248\/bpb.31.1686","volume":"31","author":"H-S Jeong","year":"2008","unstructured":"Jeong H-S, Choi H-Y, Choi T-W, Kim B-W, Kim J-H, Lee E-R, Cho S-G (2008) Differential regulation of the antiapoptotic action of B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma extra long (Bcl-xL) by c-Jun N-terminal protein kinase (JNK) 1-involved pathway in neuroglioma cells. Biol Pharm Bull 31(9):1686\u20131690","journal-title":"Biol Pharm Bull"},{"key":"4591_CR62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbacli.2015.11.002","volume":"5","author":"A Jurjus","year":"2016","unstructured":"Jurjus A, Eid A, Al Kattar S, Zeenny MN, Gerges-Geagea A, Haydar H, Hilal A, Oueidat D, Matar M, Tawilah J, Hussein IH, Schembri-Wismayer P, Cappello F, Tomasello G, Leone A, Jurjus RA (2016) Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: the links. BBA Clin 5:16\u201324. https:\/\/doi.org\/10.1016\/j.bbacli.2015.11.002","journal-title":"BBA Clin"},{"issue":"2","key":"4591_CR63","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.1152\/ajpendo.00388.2009","volume":"298","author":"Y Kanda","year":"2010","unstructured":"Kanda Y, Shimoda M, Hamamoto S, Tawaramoto K, Kawasaki F, Hashiramoto M, Nakashima K, Matsuki M, Kaku K (2010) Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Am J Physiol Endocrinol Metab 298(2):E278-286. https:\/\/doi.org\/10.1152\/ajpendo.00388.2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"4591_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8030343","volume":"8","author":"EA Kang","year":"2019","unstructured":"Kang EA, Han K, Chun J, Soh H, Park S, Im JP, Kim JS (2019) Increased risk of diabetes in inflammatory bowel disease patients: a nationwide population-based study in Korea. J Clin Med 8(3):343","journal-title":"J Clin Med"},{"issue":"2","key":"4591_CR65","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/01.MIB.0000200345.38837.46","volume":"12","author":"K Karmiris","year":"2006","unstructured":"Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA (2006) Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 12(2):100\u2013105","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"4591_CR66","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2165\/00002018-200831100-00003","volume":"31","author":"R Kasliwal","year":"2008","unstructured":"Kasliwal R, Wilton LV, Shakir SA (2008) Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf 31(10):839\u2013850. https:\/\/doi.org\/10.2165\/00002018-200831100-00003","journal-title":"Drug Saf"},{"key":"4591_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.726707","volume":"12","author":"H Ke","year":"2021","unstructured":"Ke H, Li F, Deng W, Li Z, Wang S, Lv P, Chen Y (2021) Metformin exerts anti-inflammatory and mucus barrier protective effects by enriching Akkermansia muciniphila in mice with ulcerative colitis. Front Pharmacol 12:726707. https:\/\/doi.org\/10.3389\/fphar.2021.726707","journal-title":"Front Pharmacol"},{"issue":"3","key":"4591_CR68","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bcp.12822","volume":"81","author":"W Klein-Schwartz","year":"2016","unstructured":"Klein-Schwartz W, Stassinos GL, Isbister GK (2016) Treatment of sulfonylurea and insulin overdose. Br J Clin Pharmacol 81(3):496\u2013504. https:\/\/doi.org\/10.1111\/bcp.12822","journal-title":"Br J Clin Pharmacol"},{"key":"4591_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/jir.S86917","volume":"9","author":"V Kothari","year":"2016","unstructured":"Kothari V, Galdo JA, Mathews ST (2016) Hypoglycemic agents and potential anti-inflammatory activity. J Inflamm Res 9:27\u201338. https:\/\/doi.org\/10.2147\/jir.S86917","journal-title":"J Inflamm Res"},{"issue":"9","key":"4591_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135858","volume":"10","author":"SY Lee","year":"2015","unstructured":"Lee SY, Lee SH, Yang EJ, Kim EK, Kim JK, Shin DY, Cho ML (2015) Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17\/Treg balance. PLoS ONE 10(9):e0135858. https:\/\/doi.org\/10.1371\/journal.pone.0135858","journal-title":"PLoS ONE"},{"key":"4591_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104835","volume":"158","author":"M Leppkes","year":"2020","unstructured":"Leppkes M, Neurath MF (2020) Cytokines in inflammatory bowel diseases - update 2020. Pharmacol Res 158:104835. https:\/\/doi.org\/10.1016\/j.phrs.2020.104835","journal-title":"Pharmacol Res"},{"issue":"3","key":"4591_CR72","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1053\/j.gastro.2007.12.012","volume":"134","author":"JD Lewis","year":"2008","unstructured":"Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD (2008) Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134(3):688\u2013695. https:\/\/doi.org\/10.1053\/j.gastro.2007.12.012","journal-title":"Gastroenterology"},{"issue":"18","key":"4591_CR73","doi-asserted-by":"publisher","first-page":"12966","DOI":"10.1021\/acs.jmedchem.3c00894","volume":"66","author":"Z Li","year":"2023","unstructured":"Li Z, Chen Y, Jiang X, Lu P, Wang C, Li Z, Yu X, Yang Z, Ma S, Du S, Tai Z, Li X, Zhang S, Jiang Y, Qin C (2023) Novel sulfonylurea-based NLRP3 inflammasome inhibitor for efficient treatment of nonalcoholic steatohepatitis, endotoxic shock, and colitis. J Med Chem 66(18):12966\u201312989. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00894","journal-title":"J Med Chem"},{"issue":"1","key":"4591_CR74","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3748\/wjg.14.114","volume":"14","author":"HL Liang","year":"2008","unstructured":"Liang HL, Ouyang Q (2008) A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol 14(1):114\u2013119. https:\/\/doi.org\/10.3748\/wjg.14.114","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4591_CR75","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1080\/10520295.2020.1776896","volume":"96","author":"X Liu","year":"2021","unstructured":"Liu X, Sun Z, Wang H (2021) Metformin alleviates experimental colitis in mice by up-regulating TGF-\u03b2 signaling. Biotech Histochem 96(2):146\u2013152. https:\/\/doi.org\/10.1080\/10520295.2020.1776896","journal-title":"Biotech Histochem"},{"issue":"3","key":"4591_CR76","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.mib.0000160805.46235.eb","volume":"11","author":"C Lytle","year":"2005","unstructured":"Lytle C, Tod TJ, Vo KT, Lee JW, Atkinson RD, Straus DS (2005) The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 11(3):231\u2013243. https:\/\/doi.org\/10.1097\/01.mib.0000160805.46235.eb","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"4591_CR77","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, Gonz\u00e1lez-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustin\u0161 E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J (2019) ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144\u2013164. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy113","journal-title":"J Crohns Colitis"},{"issue":"1","key":"4591_CR78","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10787-023-01227-8","volume":"32","author":"A Makaro","year":"2024","unstructured":"Makaro A, \u015awierczy\u0144ski M, Pokora K, Sarniak B, Kordek R, Fichna J, Salaga M (2024) Empagliflozin attenuates intestinal inflammation through suppression of nitric oxide synthesis and myeloperoxidase activity in in vitro and in vivo models of colitis. Inflammopharmacology 32(1):377\u2013392. https:\/\/doi.org\/10.1007\/s10787-023-01227-8","journal-title":"Inflammopharmacology"},{"issue":"1","key":"4591_CR79","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/MOG.0b013e32834c453e","volume":"28","author":"EA Mann","year":"2012","unstructured":"Mann EA, Saeed SA (2012) Gastrointestinal infection as a trigger for inflammatory bowel disease. Curr Opin Gastroenterol 28(1):24\u201329. https:\/\/doi.org\/10.1097\/MOG.0b013e32834c453e","journal-title":"Curr Opin Gastroenterol"},{"key":"4591_CR80","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/845672","volume":"2012","author":"JW Mao","year":"2012","unstructured":"Mao JW, Tang HY, Wang YD (2012) Influence of rosiglitazone on the expression of PPAR\u03b3, NF-\u03baB, and TNF-\u03b1 in rat model of ulcerative colitis. Gastroenterol Res Pract 2012:845672. https:\/\/doi.org\/10.1155\/2012\/845672","journal-title":"Gastroenterol Res Pract"},{"key":"4591_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1010693","volume":"9","author":"A Mascolo","year":"2022","unstructured":"Mascolo A, Di Napoli R, Balzano N, Cappetta D, Urbanek K, De Angelis A, Scisciola L, Di Meo I, Sullo MG, Rafaniello C, Sportiello L (2022) Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary. Front Cardiovasc Med 9:1010693. https:\/\/doi.org\/10.3389\/fcvm.2022.1010693","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"4591_CR82","doi-asserted-by":"publisher","first-page":"G623","DOI":"10.1152\/ajpgi.00392.2012","volume":"304","author":"R Mathias","year":"2013","unstructured":"Mathias R, von der Weid PY (2013) Involvement of the NO-cGMP-K(ATP) channel pathway in the mesenteric lymphatic pump dysfunction observed in the guinea pig model of TNBS-induced ileitis. Am J Physiol Gastrointest Liver Physiol 304(6):G623-634. https:\/\/doi.org\/10.1152\/ajpgi.00392.2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"4591_CR83","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2009.08.012","volume":"31","author":"CL Maynard","year":"2009","unstructured":"Maynard CL, Weaver CT (2009) Intestinal effector t cells in health and disease. Immunity 31(3):389\u2013400","journal-title":"Immunity"},{"issue":"3","key":"4591_CR84","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/gut.35.3.360","volume":"35","author":"P Munkholm","year":"1994","unstructured":"Munkholm P, Langholz E, Davidsen M, Binder V (1994) Frequency of glucocorticoid resistance and dependency in Crohn\u2019s disease. Gut 35(3):360\u2013362","journal-title":"Gut"},{"issue":"1","key":"4591_CR85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12569","volume":"280","author":"LE Mu\u00f1oz","year":"2017","unstructured":"Mu\u00f1oz LE, Leppkes M, Fuchs TA, Hoffmann M, Herrmann M (2017) Missing in action-the meaning of cell death in tissue damage and inflammation. Immunol Rev 280(1):26\u201340. https:\/\/doi.org\/10.1111\/imr.12569","journal-title":"Immunol Rev"},{"key":"4591_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1390351","volume":"15","author":"P Muro","year":"2024","unstructured":"Muro P, Zhang L, Li S, Zhao Z, Jin T, Mao F, Mao Z (2024) The emerging role of oxidative stress in inflammatory bowel disease. Front Endocrinol (Lausanne) 15:1390351. https:\/\/doi.org\/10.3389\/fendo.2024.1390351","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4591_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.975912","volume":"13","author":"K Nabrdalik","year":"2022","unstructured":"Nabrdalik K, Skonieczna-\u017bydecka K, Irlik K, Hendel M, Kwiendacz H, \u0141oniewski I, Januszkiewicz K, Gumprecht J, Lip GYH (2022) Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: a systematic review, meta-analysis and meta-regression of randomized controlled trials. Front Endocrinol (Lausanne) 13:975912. https:\/\/doi.org\/10.3389\/fendo.2022.975912","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"4591_CR88","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12876-023-02958-2","volume":"23","author":"F Nazari-Khanamiri","year":"2023","unstructured":"Nazari-Khanamiri F, Jafari A, Esmaeilzadeh Z, Ghasemnejad-Berenji M (2023) Biochemical and histopathological evidence for beneficial effects of empagliflozin pretreatment on acetic acid-induced colitis in rats. BMC Gastroenterol 23(1):332. https:\/\/doi.org\/10.1186\/s12876-023-02958-2","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"4591_CR89","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00281-019-00751-6","volume":"41","author":"MF Neurath","year":"2019","unstructured":"Neurath MF, Leppkes M (2019) Resolution of ulcerative colitis. Semin Immunopathol 41(6):747\u2013756. https:\/\/doi.org\/10.1007\/s00281-019-00751-6","journal-title":"Semin Immunopathol"},{"issue":"10114","key":"4591_CR90","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/s0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114):2769\u20132778. https:\/\/doi.org\/10.1016\/s0140-6736(17)32448-0","journal-title":"Lancet"},{"issue":"10","key":"4591_CR91","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrgastro.2017.88","volume":"14","author":"J Ni","year":"2017","unstructured":"Ni J, Wu GD, Albenberg L, Tomov VT (2017) Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 14(10):573\u2013584. https:\/\/doi.org\/10.1038\/nrgastro.2017.88","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"4591_CR92","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s12013-023-01164-x","volume":"81","author":"A Niknejad","year":"2023","unstructured":"Niknejad A, Hosseini Y, Shamsnia HS, Kashani AS, Rostamian F, Momtaz S, Abdolghaffari AH (2023) Sodium glucose transporter-2 inhibitors (SGLT2Is)-TLRs axis modulates diabetes. Cell Biochem Biophys 81(4):599\u2013613. https:\/\/doi.org\/10.1007\/s12013-023-01164-x","journal-title":"Cell Biochem Biophys"},{"issue":"11","key":"4591_CR93","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/s41401-020-0413-7","volume":"41","author":"MM Ning","year":"2020","unstructured":"Ning MM, Yang WJ, Guan WB, Gu YP, Feng Y, Leng Y (2020) Dipeptidyl peptidase 4 inhibitor sitagliptin protected against dextran sulfate sodium-induced experimental colitis by potentiating the action of GLP-2. Acta Pharmacol Sin 41(11):1446\u20131456. https:\/\/doi.org\/10.1038\/s41401-020-0413-7","journal-title":"Acta Pharmacol Sin"},{"key":"4591_CR94","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.biopha.2017.08.020","volume":"94","author":"A Pandey","year":"2017","unstructured":"Pandey A, Verma S, Kumar VL (2017) Metformin maintains mucosal integrity in experimental model of colitis by inhibiting oxidative stress and pro-inflammatory signaling. Biomed Pharmacother 94:1121\u20131128. https:\/\/doi.org\/10.1016\/j.biopha.2017.08.020","journal-title":"Biomed Pharmacother"},{"issue":"17","key":"4591_CR95","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","volume":"24","author":"SC Park","year":"2018","unstructured":"Park SC, Jeen YT (2018) Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 24(17):1868\u20131880. https:\/\/doi.org\/10.3748\/wjg.v24.i17.1868","journal-title":"World J Gastroenterol"},{"key":"4591_CR96","doi-asserted-by":"publisher","DOI":"10.1177\/1179551419844521","volume":"12","author":"V Pathak","year":"2019","unstructured":"Pathak V, Pathak NM, O\u2019Neill CL, Guduric-Fuchs J, Medina RJ (2019) Therapies for type 1 diabetes: current scenario and future perspectives. Clin Med Insights Endocrinol Diabetes 12:1179551419844521. https:\/\/doi.org\/10.1177\/1179551419844521","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"2","key":"4591_CR97","doi-asserted-by":"publisher","first-page":"132","DOI":"10.7326\/0003-4819-123-2-199507150-00009","volume":"123","author":"DC Pearson","year":"1995","unstructured":"Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123(2):132\u2013142. https:\/\/doi.org\/10.7326\/0003-4819-123-2-199507150-00009","journal-title":"Ann Intern Med"},{"issue":"7","key":"4591_CR98","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/ajg.2009.749","volume":"105","author":"G Pedersen","year":"2010","unstructured":"Pedersen G, Brynskov J (2010) Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. Am J Gastroenterol 105(7):1595\u20131603. https:\/\/doi.org\/10.1038\/ajg.2009.749","journal-title":"Am J Gastroenterol"},{"key":"4591_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-018-0419-3","volume":"25","author":"Y-J Peng","year":"2018","unstructured":"Peng Y-J, Shen T-L, Chen Y-S, Mersmann HJ, Liu B-H, Ding S-T (2018) Adiponectin and adiponectin receptor 1 overexpression enhance inflammatory bowel disease. J Biomed Sci 25:1\u201313","journal-title":"J Biomed Sci"},{"issue":"4","key":"4591_CR100","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/s2213-8587(20)30021-8","volume":"8","author":"I Pernicova","year":"2020","unstructured":"Pernicova I, Kelly S, Ajodha S, Sahdev A, Bestwick JP, Gabrovska P, Akanle O, Ajjan R, Kola B, Stadler M, Fraser W, Christ-Crain M, Grossman AB, Pitzalis C, Korbonits M (2020) Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol 8(4):278\u2013291. https:\/\/doi.org\/10.1016\/s2213-8587(20)30021-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4591_CR101","doi-asserted-by":"crossref","unstructured":"Peterson, R. L., L. Wang, L. Albert, J. C. Keith Jr and A. J. Dorner (1998). \"Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease.\" Laboratory investigation; a journal of technical methods and pathology 78(12), 1503\u20131512.","DOI":"10.1016\/S0016-5085(98)84313-8"},{"key":"4591_CR102","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae147","author":"JC Petrov","year":"2024","unstructured":"Petrov JC, Desai AA, Kochhar GS, Crosby SK, Kinnucan JA, Picco MF, Hashash JG, Farraye FA (2024) Metformin is associated with improved inflammatory bowel disease outcomes in patients with type 2 diabetes mellitus: a propensity-matched cohort study. Inflamm Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izae147","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"4591_CR103","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.4049\/jimmunol.0903987","volume":"184","author":"AM Platt","year":"2010","unstructured":"Platt AM, Bain CC, Bordon Y, Sester DP, Mowat AM (2010) An independent subset of TLR expressing CCR2-dependent macrophages promotes colonic inflammation. J Immunol 184(12):6843\u20136854. https:\/\/doi.org\/10.4049\/jimmunol.0903987","journal-title":"J Immunol"},{"key":"4591_CR104","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/jir.s441231","volume":"17","author":"X Qing","year":"2024","unstructured":"Qing X, Wang L, Fang S, Ban Y, Zhong Z, Sun W, Zhang C, Zhang T, Yang Y, Wei W (2024) Association of antidiabetic drug target genes with inflammatory bowel disease: a mendelian randomization study. J Inflamm Res 17:1389\u20131396. https:\/\/doi.org\/10.2147\/jir.s441231","journal-title":"J Inflamm Res"},{"issue":"12","key":"4591_CR105","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1080\/17474124.2018.1545574","volume":"12","author":"SM Quezada","year":"2018","unstructured":"Quezada SM, McLean LP, Cross RK (2018) Adverse events in IBD therapy: the 2018 update. Expert Rev Gastroenterol Hepatol 12(12):1183\u20131191","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"4591_CR106","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10875-007-9074-2","volume":"27","author":"JD Ramakers","year":"2007","unstructured":"Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink RP, Plat J (2007) The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol 27(3):275\u2013283. https:\/\/doi.org\/10.1007\/s10875-007-9074-2","journal-title":"J Clin Immunol"},{"issue":"2","key":"4591_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.102949","volume":"18","author":"SM Razavi","year":"2024","unstructured":"Razavi SM, Arab ZN, Niknejad A, Hosseini Y, Fouladi A, Khales SD, Shahali M, Momtaz S, Butler AE, Sukhorukov VN, Jamialahmadi T, Abdolghaffari AH, Sahebkar A (2024) Therapeutic effects of anti-diabetic drugs on traumatic brain injury. Diabetes Metab Syndr 18(2):102949. https:\/\/doi.org\/10.1016\/j.dsx.2024.102949","journal-title":"Diabetes Metab Syndr"},{"issue":"Suppl 3","key":"4591_CR108","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2362.1994.tb02251.x","volume":"24","author":"AJ Reuser","year":"1994","unstructured":"Reuser AJ, Wisselaar HA (1994) An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 24(Suppl 3):19\u201324. https:\/\/doi.org\/10.1111\/j.1365-2362.1994.tb02251.x","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"4591_CR109","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/gut.2006.111872","volume":"56","author":"JM Rhodes","year":"2007","unstructured":"Rhodes JM (2007) The role of Escherichia coli in inflammatory bowel disease. Gut 56(5):610\u2013612. https:\/\/doi.org\/10.1136\/gut.2006.111872","journal-title":"Gut"},{"issue":"11","key":"4591_CR110","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","volume":"169","author":"MJ Rosen","year":"2015","unstructured":"Rosen MJ, Dhawan A, Saeed SA (2015) Inflammatory bowel disease in children and adolescents. JAMA Pediatr 169(11):1053\u20131060","journal-title":"JAMA Pediatr"},{"issue":"1","key":"4591_CR111","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10787-020-00730-6","volume":"29","author":"S Saber","year":"2021","unstructured":"Saber S, El-Kader EMA (2021) Novel complementary coloprotective effects of metformin and MCC950 by modulating HSP90\/NLRP3 interaction and inducing autophagy in rats. Inflammopharmacology 29(1):237\u2013251. https:\/\/doi.org\/10.1007\/s10787-020-00730-6","journal-title":"Inflammopharmacology"},{"issue":"3","key":"4591_CR112","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.pharep.2017.11.015","volume":"70","author":"FS Samman","year":"2018","unstructured":"Samman FS, Elaidy SM, Essawy SS, Hassan MS (2018) New insights on the modulatory roles of metformin or alpha-lipoic acid versus their combination in dextran sulfate sodium-induced chronic colitis in rats. Pharmacol Rep 70(3):488\u2013496. https:\/\/doi.org\/10.1016\/j.pharep.2017.11.015","journal-title":"Pharmacol Rep"},{"issue":"12","key":"4591_CR113","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.bcp.2005.03.024","volume":"69","author":"M S\u00e1nchez-Hidalgo","year":"2005","unstructured":"S\u00e1nchez-Hidalgo M, Mart\u00edn AR, Villegas I, Alarc\u00f3n De La Lastra C (2005) Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 69(12):1733\u20131744. https:\/\/doi.org\/10.1016\/j.bcp.2005.03.024","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"4591_CR114","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejphar.2007.01.047","volume":"562","author":"M S\u00e1nchez-Hidalgo","year":"2007","unstructured":"S\u00e1nchez-Hidalgo M, Mart\u00edn AR, Villegas I, de la Lastra CA (2007) Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur J Pharmacol 562(3):247\u2013258. https:\/\/doi.org\/10.1016\/j.ejphar.2007.01.047","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"4591_CR115","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/S0016-5085(00)70007-2","volume":"118","author":"BE Sands","year":"2000","unstructured":"Sands BE (2000) Therapy of inflammatory bowel disease. Gastroenterology 118(2):S68\u2013S82","journal-title":"Gastroenterology"},{"issue":"10","key":"4591_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26104818","volume":"26","author":"MI San-Martin","year":"2025","unstructured":"San-Martin MI, Chamizo-Ampudia A, Sanchiz \u00c1, Ferrero M\u00c1, Mart\u00ednez-Blanco H, Rodr\u00edguez-Aparicio LB, Navasa N (2025) Microbiome markers in gastrointestinal disorders: inflammatory bowel disease, colorectal cancer, and celiac disease. Int J Mol Sci 26(10):4818","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4591_CR117","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00054725-200209000-00004","volume":"8","author":"LJ Saubermann","year":"2002","unstructured":"Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, Aburatani H, Matsuhashi N, Nagai R, Blumberg RS (2002) Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 8(5):330\u2013339. https:\/\/doi.org\/10.1097\/00054725-200209000-00004","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"4591_CR118","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/01.mib.0000160770.94199.9b","volume":"11","author":"KL Schaefer","year":"2005","unstructured":"Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ (2005) Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 11(3):244\u2013252. https:\/\/doi.org\/10.1097\/01.mib.0000160770.94199.9b","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"4591_CR119","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/00325481.2015.1043182","volume":"127","author":"S Schwartz","year":"2015","unstructured":"Schwartz S, Herman M (2015) Revisiting weight reduction and management in the diabetic patient: novel therapies provide new strategies. Postgrad Med 127(5):480\u2013493. https:\/\/doi.org\/10.1080\/00325481.2015.1043182","journal-title":"Postgrad Med"},{"issue":"2","key":"4591_CR120","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40265-016-0686-9","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ (2017) Sitagliptin: a review in type 2 diabetes. Drugs 77(2):209\u2013224. https:\/\/doi.org\/10.1007\/s40265-016-0686-9","journal-title":"Drugs"},{"issue":"3","key":"4591_CR121","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1530\/eje-16-0653","volume":"176","author":"E Seelig","year":"2017","unstructured":"Seelig E, Meyer S, Timper K, Nigro N, Bally M, Pernicova I, Schuetz P, M\u00fcller B, Korbonits M, Christ-Crain M (2017) Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol 176(3):349\u2013358. https:\/\/doi.org\/10.1530\/eje-16-0653","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"4591_CR122","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/ni1309","volume":"7","author":"NV Serbina","year":"2006","unstructured":"Serbina NV, Pamer EG (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 7(3):311\u2013317. https:\/\/doi.org\/10.1038\/ni1309","journal-title":"Nat Immunol"},{"key":"4591_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113247","volume":"153","author":"AA Shaaban","year":"2022","unstructured":"Shaaban AA, Abdelhamid AM, Shaker ME, Cavalu S, Maghiar AM, Alsayegh AA, Babalghith AO, El-Ahwany E, Amin NA, Mohammed OA, Eissa H, Gaafar AGA, Batiha GE, Saber S (2022) Combining the HSP90 inhibitor TAS-116 with metformin effectively degrades the NLRP3 and attenuates inflammasome activation in rats: a new management paradigm for ulcerative colitis. Biomed Pharmacother 153:113247. https:\/\/doi.org\/10.1016\/j.biopha.2022.113247","journal-title":"Biomed Pharmacother"},{"key":"4591_CR124","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-042320-021020","volume":"73","author":"Y Shan","year":"2022","unstructured":"Shan Y, Lee M, Chang EB (2022) The gut microbiome and inflammatory bowel diseases. Annu Rev Med 73:455\u2013468. https:\/\/doi.org\/10.1146\/annurev-med-042320-021020","journal-title":"Annu Rev Med"},{"issue":"4","key":"4591_CR125","first-page":"257","volume":"19","author":"F Shanahan","year":"2016","unstructured":"Shanahan F, Sheehan D (2016) Microbial contributions to chronic inflammation and metabolic disease. Curr Opin Clin Nutr Metab Care 19(4):257\u2013262","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"4591_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2015.00095","volume":"5","author":"RC Sharp","year":"2015","unstructured":"Sharp RC, Abdulrahim M, Naser ES, Naser SA (2015) Genetic variations of PTPN2 and PTPN22: role in the pathogenesis of type 1 diabetes and Crohn\u2019s disease. Front Cell Infect Microbiol 5:95","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"4591_CR127","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1038\/ajg.2010.398","volume":"105","author":"SY Shaw","year":"2010","unstructured":"Shaw SY, Blanchard JF, Bernstein CN (2010) Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol 105(12):2687\u20132692","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"4591_CR128","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0002-9343(81)90773-7","volume":"70","author":"TG Skillman","year":"1981","unstructured":"Skillman TG, Feldman JM (1981) The pharmacology of sulfonylureas. Am J Med 70(2):361\u2013372. https:\/\/doi.org\/10.1016\/0002-9343(81)90773-7","journal-title":"Am J Med"},{"issue":"3","key":"4591_CR129","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1189\/jlb.1005566","volume":"80","author":"LE Smythies","year":"2006","unstructured":"Smythies LE, Maheshwari A, Clements R, Eckhoff D, Novak L, Vu HL, Mosteller-Barnum LM, Sellers M, Smith PD (2006) Mucosal IL-8 and TGF-beta recruit blood monocytes: evidence for cross-talk between the lamina propria stroma and myeloid cells. J Leukoc Biol 80(3):492\u2013499. https:\/\/doi.org\/10.1189\/jlb.1005566","journal-title":"J Leukoc Biol"},{"issue":"4","key":"4591_CR130","doi-asserted-by":"publisher","first-page":"840","DOI":"10.5114\/aoms.2015.53304","volume":"11","author":"D Sola","year":"2015","unstructured":"Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, Corlian\u00f2 F, Fra GP, Bartoli E, Derosa G (2015) Sulfonylureas and their use in clinical practice. Arch Med Sci 11(4):840\u2013848. https:\/\/doi.org\/10.5114\/aoms.2015.53304","journal-title":"Arch Med Sci"},{"issue":"5","key":"4591_CR131","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1179\/135100002125000802","volume":"7","author":"T Takagi","year":"2002","unstructured":"Takagi T, Naito Y, Tomatsuri N, Handa O, Ichikawa H, Yoshida N, Yoshikawa T (2002) Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade. Redox Rep 7(5):283\u2013289. https:\/\/doi.org\/10.1179\/135100002125000802","journal-title":"Redox Rep"},{"issue":"2","key":"4591_CR132","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100831RR","volume":"36","author":"M Takahara","year":"2022","unstructured":"Takahara M, Takaki A, Hiraoka S, Takei K, Yasutomi E, Igawa S, Yamamoto S, Oka S, Ohmori M, Yamasaki Y, Inokuchi T, Kinugasa H, Harada K, Udono H, Okada H (2022) Metformin ameliorates chronic colitis in a mouse model by regulating interferon-\u03b3-producing lamina propria CD4(+) T cells through AMPK activation. FASEB J 36(2):e22139. https:\/\/doi.org\/10.1096\/fj.202100831RR","journal-title":"FASEB J"},{"issue":"1","key":"4591_CR133","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00011-005-0002-8","volume":"55","author":"K Takaki","year":"2006","unstructured":"Takaki K, Mitsuyama K, Tsuruta O, Toyonaga A, Sata M (2006) Attenuation of experimental colonic injury by thiazolidinedione agents. Inflamm Res 55(1):10\u201315. https:\/\/doi.org\/10.1007\/s00011-005-0002-8","journal-title":"Inflamm Res"},{"key":"4591_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/phrs.2021.1603990","volume":"42","author":"P Tavakoli","year":"2021","unstructured":"Tavakoli P, Vollmer-Conna U, Hadzi-Pavlovic D, Grimm MC (2021) A review of inflammatory bowel disease: a model of microbial, immune and neuropsychological integration. Public Health Rev 42:1603990. https:\/\/doi.org\/10.3389\/phrs.2021.1603990","journal-title":"Public Health Rev"},{"issue":"1","key":"4591_CR135","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clim.2004.03.002","volume":"112","author":"H-P T\u00f6r\u00f6k","year":"2004","unstructured":"T\u00f6r\u00f6k H-P, Glas J, Tonenchi L, Mussack T, Folwaczny C (2004) Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol 112(1):85\u201391","journal-title":"Clin Immunol"},{"key":"4591_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123001","volume":"355","author":"J Tran","year":"2024","unstructured":"Tran J, Parekh S, Rockcole J, Wilson D, Parmar MS (2024) Repurposing antidiabetic drugs for Alzheimer\u2019s disease: a review of preclinical and clinical evidence and overcoming challenges. Life Sci 355:123001. https:\/\/doi.org\/10.1016\/j.lfs.2024.123001","journal-title":"Life Sci"},{"issue":"15","key":"4591_CR137","first-page":"3336","volume":"2018","author":"F Trejo-Vazquez","year":"2018","unstructured":"Trejo-Vazquez F, Garza-Veloz I, Villela-Ramirez G, Ortiz-Castro Y, Mauricio-Saucedo P, Cardenas-Vargas E (2018) Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: a case-control study. Exp Ther Med 2018(15):3336\u20133344","journal-title":"Exp Ther Med"},{"key":"4591_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/ph15121538","author":"CH Tseng","year":"2022","unstructured":"Tseng CH (2022) Pioglitazone has a null association with inflammatory bowel disease in patients with type 2 diabetes mellitus. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph15121538","journal-title":"Pharmaceuticals (Basel)"},{"key":"4591_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ph16050679","author":"CH Tseng","year":"2023","unstructured":"Tseng CH (2023) Rosiglitazone does not affect the risk of inflammatory bowel disease: a retrospective cohort study in Taiwanese type 2 diabetes patients. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph16050679","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5\u20136","key":"4591_CR140","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000333793","volume":"88","author":"D Tung","year":"2011","unstructured":"Tung D, Cheung PH, Ciallella J, Saha S (2011) Novel anti-inflammatory effects of repaglinide in rodent models of inflammation. Pharmacology 88(5\u20136):295\u2013301. https:\/\/doi.org\/10.1159\/000333793","journal-title":"Pharmacology"},{"key":"4591_CR141","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.11.7519","author":"J Turkson","year":"1999","unstructured":"Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S (1999) Requirement for Ras\/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol. https:\/\/doi.org\/10.1128\/MCB.19.11.7519","journal-title":"Mol Cell Biol"},{"key":"4591_CR142","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00535-018-1449-z","volume":"53","author":"B Verstockt","year":"2018","unstructured":"Verstockt B, Ferrante M, Vermeire S, Van Assche G (2018) New treatment options for inflammatory bowel diseases. J Gastroenterol 53:585\u2013590","journal-title":"J Gastroenterol"},{"key":"4591_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109230","volume":"112","author":"W Wanchaitanawong","year":"2022","unstructured":"Wanchaitanawong W, Thinrungroj N, Chattipakorn SC, Chattipakorn N, Shinlapawittayatorn K (2022) Repurposing metformin as a potential treatment for inflammatory bowel disease: evidence from cell to the clinic. Int Immunopharmacol 112:109230. https:\/\/doi.org\/10.1016\/j.intimp.2022.109230","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"4591_CR144","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/15384047.2018.1529108","volume":"20","author":"SQ Wang","year":"2019","unstructured":"Wang SQ, Cui SX, Qu XJ (2019) Metformin inhibited colitis and colitis-associated cancer (CAC) through protecting mitochondrial structures of colorectal epithelial cells in mice. Cancer Biol Ther 20(3):338\u2013348. https:\/\/doi.org\/10.1080\/15384047.2018.1529108","journal-title":"Cancer Biol Ther"},{"key":"4591_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.887497","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang Z, Yang H, Chen S, Zheng D, Liu X, Jiang Q, Chen Y (2022) Metformin ameliorates chronic colitis-related intestinal fibrosis via inhibiting TGF-\u03b21\/Smad3 signaling. Front Pharmacol 13:887497. https:\/\/doi.org\/10.3389\/fphar.2022.887497","journal-title":"Front Pharmacol"},{"issue":"2","key":"4591_CR146","first-page":"264","volume":"2","author":"S Wilks","year":"1859","unstructured":"Wilks S (1859) Morbid appearances in the intestine of Miss Bankes. Med Times Gaz 2(2):264\u2013265","journal-title":"Med Times Gaz"},{"issue":"1","key":"4591_CR147","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00719-x","volume":"14","author":"W Wu","year":"2023","unstructured":"Wu W, Wang Y, Xie J, Fan S (2023) Empagliflozin: a potential anticancer drug. Discov Oncol 14(1):127. https:\/\/doi.org\/10.1007\/s12672-023-00719-x","journal-title":"Discov Oncol"},{"issue":"3","key":"4591_CR148","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1124\/jpet.114.221572","volume":"352","author":"S Yang","year":"2015","unstructured":"Yang S, Jan YH, Mishin V, Richardson JR, Hossain MM, Heindel ND, Heck DE, Laskin DL, Laskin JD (2015) Sulfa drugs inhibit sepiapterin reduction and chemical redox cycling by sepiapterin reductase. J Pharmacol Exp Ther 352(3):529\u2013540. https:\/\/doi.org\/10.1124\/jpet.114.221572","journal-title":"J Pharmacol Exp Ther"},{"key":"4591_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652709","volume":"12","author":"S Yang","year":"2021","unstructured":"Yang S, Park JS, Hwang SH, Cho KH, Na HS, Choi J, Jhun J, Kim SJ, Lee BI, Park SH, Cho ML (2021) Metformin-inducible small heterodimer partner interacting leucine zipper protein ameliorates intestinal inflammation. Front Immunol 12:652709. https:\/\/doi.org\/10.3389\/fimmu.2021.652709","journal-title":"Front Immunol"},{"key":"4591_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117152","volume":"241","author":"H Yaribeygi","year":"2020","unstructured":"Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A (2020) Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes. Life Sci 241:117152. https:\/\/doi.org\/10.1016\/j.lfs.2019.117152","journal-title":"Life Sci"},{"key":"4591_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.719984","volume":"12","author":"ME Youssef","year":"2021","unstructured":"Youssef ME, Abd El-Fattah EE, Abdelhamid AM, Eissa H, El-Ahwany E, Amin NA, Hetta HF, Mahmoud MH, Batiha GE, Gobba N, Ahmed Gaafar AG, Saber S (2021) Interference with the AMPK\u03b1\/mTOR\/NLRP3 signaling and the IL-23\/IL-17 axis effectively protects against the dextran sulfate sodium intoxication in rats: a new paradigm in empagliflozin and metformin reprofiling for the management of ulcerative colitis. Front Pharmacol 12:719984. https:\/\/doi.org\/10.3389\/fphar.2021.719984","journal-title":"Front Pharmacol"},{"key":"4591_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2022.103833","volume":"91","author":"MS Zaghloul","year":"2022","unstructured":"Zaghloul MS, Elshal M, Abdelmageed ME (2022) Preventive empagliflozin activity on acute acetic acid-induced ulcerative colitis in rats via modulation of SIRT-1\/PI3K\/AKT pathway and improving colon barrier. Environ Toxicol Pharmacol 91:103833. https:\/\/doi.org\/10.1016\/j.etap.2022.103833","journal-title":"Environ Toxicol Pharmacol"},{"key":"4591_CR153","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9860855","volume":"2022","author":"MY Zamanian","year":"2022","unstructured":"Zamanian MY, Taheri N, Opulencia MJC, Bokov DO, Abdullaev SY, Gholamrezapour M, Heidari M, Bazmandegan G (2022) Neuroprotective and anti-inflammatory effects of pioglitazone on traumatic brain injury. Mediators Inflamm 2022:9860855. https:\/\/doi.org\/10.1155\/2022\/9860855","journal-title":"Mediators Inflamm"},{"issue":"3","key":"4591_CR154","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2174\/1874467215666220620143655","volume":"16","author":"MY Zamanian","year":"2023","unstructured":"Zamanian MY, Gim\u00e9nez-Llort L, Nikbakhtzadeh M, Kamiab Z, Heidari M, Bazmandegan G (2023) The therapeutic activities of metformin: focus on the Nrf2 signaling pathway and oxidative stress amelioration. Curr Mol Pharmacol 16(3):331\u2013345. https:\/\/doi.org\/10.2174\/1874467215666220620143655","journal-title":"Curr Mol Pharmacol"},{"key":"4591_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108645","volume":"172","author":"S Zhang","year":"2021","unstructured":"Zhang S, Cai Y, Meng C, Ding X, Huang J, Luo X, Cao Y, Gao F, Zou M (2021) The role of the microbiome in diabetes mellitus. Diabetes Res Clin Pract 172:108645. https:\/\/doi.org\/10.1016\/j.diabres.2020.108645","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04591-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04591-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04591-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:45:27Z","timestamp":1776221127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04591-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":155,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4591"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04591-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}